Literature DB >> 10311308

Cost-effective control of rheumatic fever in the community.

T Strasser.   

Abstract

Rheumatic fever is declining rapidly in importance in the developed countries, but is still a major public health problem in the developing countries. Primary prevention techniques, consisting of the detection and antibiotic treatment of streptococcal infections of the pharynx, are both feasible and effective, but are also costly, as only 10-20% of all pharyngeal infections are due to the beta-hemolytic Streptococcus, and only a small proportion of those actually develop into rheumatic heart disease. A different concerted approach, which is both effective and economically entirely justifiable, is to use antibiotics as a prophylaxis to prevent secondary infection, i.e. relapses of rheumatic fever. A multi-centre study conducted by the WHO has shown that the cost of antibiotics used for secondary prevention was less than the savings resulting from the lower incidence and shorter hospital stays of recurrencies of rheumatic fever. Given economic restrictions, therefore, priority is given to organized and systematic secondary prevention.

Entities:  

Mesh:

Year:  1985        PMID: 10311308     DOI: 10.1016/0168-8510(85)90030-2

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  3 in total

Review 1.  Prevention and treatment of rheumatic heart disease in the developing world.

Authors:  Andrew C Steer; Jonathan R Carapetis
Journal:  Nat Rev Cardiol       Date:  2009-09-15       Impact factor: 32.419

Review 2.  Screening for rheumatic heart disease: current approaches and controversies.

Authors:  Kathryn Roberts; Samantha Colquhoun; Andrew Steer; Bo Reményi; Jonathan Carapetis
Journal:  Nat Rev Cardiol       Date:  2012-11-13       Impact factor: 32.419

3.  A Cost-Effectiveness Tool to Guide the Prioritization of Interventions for Rheumatic Fever and Rheumatic Heart Disease Control in African Nations.

Authors:  David Watkins; Solomon J Lubinga; Bongani Mayosi; Joseph B Babigumira
Journal:  PLoS Negl Trop Dis       Date:  2016-08-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.